No Data
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Earnings Miss: Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Missed EPS By 21% And Analysts Are Revising Their Forecasts
Guangzhou Baiyunshan Pharmaceutical Plans to Apply for Credit Line
BAIYUNSHAN PH (00874.HK) will release its Earnings Reports on March 14.
$BAIYUNSHAN PH (00874.HK) will release its Earnings Reports on March 14, and investors should pay attention. Futubull Reminder: 1. There are no strict regulations regarding the fiscal year division for companies listed in Hong Kong and the U.S.; it is entirely up to the company to decide, so each Earnings Reports period can serve as the cutoff date for the company's annual report, rather than being based on the calendar year. 2. Generally, the company will hold an Earnings Reports meeting on or around the release date, where the management will discuss the latest quarterly Earnings Reports data and operational status, and communicate with investors, Analysts, media, etc. Investors can.
Baiyunshan: Full text of the 2024 Annual Report of Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd.
Baiyunshan: Summary of the 2024 Annual Report of Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd.
Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Appear To Be Weighed Down